AC
ACET icon

Ascend Capital’s Adicet Bio ACET Stock Holding History

Ascend Capital’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-386
Closed -$414K – 173
2018
Q1 		$414K Buy
+386
New +$708K 0.02% 199

Other funds holding ACET

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
SCM
Segantii Capital Management Hong Kong $1.54B AUM 16.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

Ascend Capital's ACET Position: Q2 2018 in Review

Ascend Capital sold out of Adicet Bio (ACET) in Q2 2018, closing a stake of 386 shares — an estimated $414K sold.

Ascend Capital first reported a position in ACET in Q1 2018 and held it in 1 quarter. The position peaked at $414K in Q1 2018. 45 funds tracked by Wall St. Rank hold ACET as of Q2 2018.

  • Ascend Capital reported no remaining Adicet Bio position as of Q2 2018 after selling out during the quarter.
  • Ascend Capital sold 386 Adicet Bio shares in Q2 2018, an estimated $414K.
  • Ascend Capital first reported a position in Adicet Bio in Q1 2018 and held it in 1 quarter.
  • Ascend Capital's Adicet Bio position peaked at $414K in Q1 2018.
  • 45 funds tracked by Wall St. Rank held Adicet Bio as of Q2 2018.

Based on Ascend Capital's 13F filing for Q2 2018, filed 13 Aug 2018.